Top Markets
Coin of the day
IMV Inc. IMV Inc.

IMV Inc.

IMV
Pozycja w akcjach #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Cena akcji
$0.82959892
Ostatnia synchronizacja: 2023-05-23
Kapitalizacja rynkowa
$4.16M
Zmiana (1 dzień)
-0.04%
Zmiana (1 rok)
0.00%
Kraj
CA
Handel IMV Inc. (IMV)

Kategoria

EPS dla IMV Inc. (IMV)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy IMV Inc., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla IMV Inc. od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów